Search - tctmd.com

Displaying 1 - 20 of 192

Sort: Relevancy | Date

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

News Conference News TCT 2016

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Yael L. Maxwell

October 30, 2016

News Conference News TCT 2016

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Michael O'Riordan

October 29, 2016

News Conference News TCT 2015

IBIS-4: Rosuvastatin Tied to Plaque Stability in STEMI

Yael L. Maxwell

October 16, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

News Conference News TCT 2015

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

October 13, 2015

News Conference News TCT 2015

Discussion Highlights Merits, Limitations of Small Trials

Yael L. Maxwell

October 13, 2015

News Conference News TCT 2015

DAPT Study Subanalysis Focuses on EES Subgroup

October 12, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

Presentation TCT 2014

Thoughtful Insights

Presenter: Daniel I. Simon

September 17, 2014

Presentation TCT 2014

Case Presentation

Presenter: Thomas D. Stuckey

September 17, 2014

Presentation TCT 2014

Con: Follow the Data and Save the Patient!

Presenter: Adrian P. Banning, Gregg W. Stone

September 16, 2014

Presentation TCT 2014

Pro: Follow the Data - and Save the Money!

Presenter: Adrian P. Banning, Rod H. Stables

September 16, 2014

Presentation TCT 2014

VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_

Presenter: Jos? Mar?a Cubero G?mez

September 16, 2014

Presentation TCT 2014

Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE

Presenter: Fausto Feres

September 16, 2014

Presentation TCT 2014

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Presenter: Giulio Stefanini

September 16, 2014

Presentation TCT 2014

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Presenter: Timothy Henry

September 16, 2014

Presentation TCT 2014

Impact of platelet reactivity on clopidogrel after PCI with 2nd generation DES on late lumen loss_

Presenter: Naoei Isomura

September 16, 2014

Presentation TCT 2014

Heparin versus Bivalirudin in patients undergoing Percutaneous Coronary Intervention

Presenter: Ahmed Rehmani

September 16, 2014

Advertisement

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

IBIS-4: Rosuvastatin Tied to Plaque Stability in STEMI

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Safety, Efficacy Endpoints Must Be Balanced in Clinical Trials

Discussion Highlights Merits, Limitations of Small Trials

DAPT Study Subanalysis Focuses on EES Subgroup

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Thoughtful Insights

Case Presentation

Con: Follow the Data and Save the Patient!

Pro: Follow the Data - and Save the Money!

VerifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel (VERDI study)_

Two-Year Clinical Results of Patients Randomized to 3- or 12-Month Dual Antiplatelet After Endeavor Zotarolimus Eluting Stent Implantation In OPTIMIZE

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Safety and Effectiveness of Prasugrel vs_ Clopidogrel in the Setting of Bivalirudin vs_ Heparin Use: 30-day Results from TRANSLATE-ACS

Impact of platelet reactivity on clopidogrel after PCI with 2nd generation DES on late lumen loss_

Heparin versus Bivalirudin in patients undergoing Percutaneous Coronary Intervention

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content